John C. Flickinger

685 total citations
17 papers, 516 citations indexed

About

John C. Flickinger is a scholar working on Oncology, Immunology and Biotechnology. According to data from OpenAlex, John C. Flickinger has authored 17 papers receiving a total of 516 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Immunology and 5 papers in Biotechnology. Recurrent topics in John C. Flickinger's work include CAR-T cell therapy research (9 papers), Cancer Research and Treatments (4 papers) and Virus-based gene therapy research (3 papers). John C. Flickinger is often cited by papers focused on CAR-T cell therapy research (9 papers), Cancer Research and Treatments (4 papers) and Virus-based gene therapy research (3 papers). John C. Flickinger collaborates with scholars based in United States, France and India. John C. Flickinger's co-authors include Adam E. Snook, Ulrich Rodeck, Robert D. Carlson, Scott A. Waldman, Trevor R. Baybutt, Tara S. Abraham, Adam R. Hersperger, Glen P. Marszalowicz, Priyanka Prajapati and Michael S. Magee and has published in prestigious journals such as Nature Immunology, The Journal of Immunology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

John C. Flickinger

17 papers receiving 507 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John C. Flickinger United States 11 257 247 115 114 87 17 516
Roberta Rotunno Italy 11 85 0.3× 123 0.5× 70 0.6× 263 2.3× 91 1.0× 33 431
Dobrin Draganov United States 10 187 0.7× 238 1.0× 243 2.1× 26 0.2× 26 0.3× 16 569
Cornell Allen United States 13 274 1.1× 257 1.0× 378 3.3× 46 0.4× 66 0.8× 22 693
Xiang Ao China 12 196 0.8× 159 0.6× 237 2.1× 18 0.2× 57 0.7× 17 533
Catalina Martínez Colombia 8 397 1.5× 285 1.2× 146 1.3× 27 0.2× 100 1.1× 17 692
Estela Noguera-Ortega United States 11 400 1.6× 261 1.1× 210 1.8× 34 0.3× 129 1.5× 17 647
Jaina M. Patel United States 12 161 0.6× 237 1.0× 158 1.4× 15 0.1× 56 0.6× 18 408
Judit Fazekas Austria 12 152 0.6× 147 0.6× 120 1.0× 42 0.4× 28 0.3× 20 437
Chris Twitty United States 12 330 1.3× 391 1.6× 258 2.2× 75 0.7× 33 0.4× 18 654
Robert Weth Germany 11 120 0.5× 221 0.9× 107 0.9× 49 0.4× 24 0.3× 13 362

Countries citing papers authored by John C. Flickinger

Since Specialization
Citations

This map shows the geographic impact of John C. Flickinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Flickinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Flickinger more than expected).

Fields of papers citing papers by John C. Flickinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Flickinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Flickinger. The network helps show where John C. Flickinger may publish in the future.

Co-authorship network of co-authors of John C. Flickinger

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Flickinger. A scholar is included among the top collaborators of John C. Flickinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Flickinger. John C. Flickinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Flickinger, John C., Jagmohan Singh, Robert D. Carlson, et al.. (2022). Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy. npj Vaccines. 7(1). 61–61. 11 indexed citations
2.
Flickinger, John C., et al.. (2022). T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C. Frontiers in Immunology. 13. 855759–855759. 11 indexed citations
3.
Flickinger, John C., et al.. (2021). Guanylyl Cyclase C As A Biomarker for Immunotherapies for the Treatment of Gastrointestinal Malignancies. Biomarkers in Medicine. 15(3). 201–217. 1 indexed citations
4.
Flickinger, John C., et al.. (2021). GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Review of Precision Medicine and Drug Development. 6(2). 117–129. 11 indexed citations
5.
Dulmage, Brittany, et al.. (2021). Severe Refractory Hailey-Hailey Disease Treated With Electron Beam Radiotherapy and Low-Level Laser Therapy. Cutis. 107(1). E27–E30. 3 indexed citations
6.
Bashir, Babar, John C. Flickinger, & Adam E. Snook. (2021). Vaccines and Immune Checkpoint Inhibitors: a Promising Combination Strategy in Gastrointestinal Cancers. Immunotherapy. 13(7). 561–564. 2 indexed citations
7.
Flickinger, John C., Jagmohan Singh, Robert D. Carlson, et al.. (2020). Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. Journal for ImmunoTherapy of Cancer. 8(2). e001046–e001046. 27 indexed citations
8.
Carlson, Robert D., John C. Flickinger, & Adam E. Snook. (2020). Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy. Toxins. 12(4). 241–241. 66 indexed citations
9.
Snook, Adam E., Trevor R. Baybutt, Bo Xiang, et al.. (2019). Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. Journal for ImmunoTherapy of Cancer. 7(1). 104–104. 50 indexed citations
10.
Abraham, Tara S., John C. Flickinger, Scott A. Waldman, & Adam E. Snook. (2019). TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C. The Journal of Immunology. 202(4). 1301–1310. 6 indexed citations
11.
Flickinger, John C., et al.. (2019). Therapeutic Targeting of Gastrointestinal Cancer Stem Cells. Regenerative Medicine. 14(4). 331–343. 12 indexed citations
12.
Magee, Michael S., Tara S. Abraham, Trevor R. Baybutt, et al.. (2018). Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunology Research. 6(5). 509–516. 115 indexed citations
13.
Baybutt, Trevor R., John C. Flickinger, Ellen Caparosa, & Adam E. Snook. (2018). Advances in Chimeric Antigen Receptor T‐Cell Therapies for Solid Tumors. Clinical Pharmacology & Therapeutics. 105(1). 71–78. 18 indexed citations
14.
Flickinger, John C., Ulrich Rodeck, & Adam E. Snook. (2018). Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress. Vaccines. 6(3). 48–48. 90 indexed citations
15.
Kwong, Brandon, Réjane Rua, Yuanyuan Gao, et al.. (2017). T-bet-dependent NKp46+ innate lymphoid cells regulate the onset of TH17-induced neuroinflammation. Nature Immunology. 18(10). 1117–1127. 90 indexed citations
16.
Holt, Douglas E., Steven A. Burton, John C. Flickinger, et al.. (2015). Clinical Outcomes of Single Isocenter Volumetric Modulated Arc Radiosurgery for Targeting Multiple Brain Metastases. International Journal of Radiation Oncology*Biology*Physics. 93(3). E112–E113. 2 indexed citations
17.
Leeman, Jonathan E., John C. Flickinger, David A. Clump, et al.. (2012). Detection and treatment of small brain metastases resulting from renal cell carcinoma predict improved survival after stereotactic radiosurgery. Journal of Radiation Oncology. 1(4). 381–387. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberta Rotunno Breakdown of academic impact, for papers by Dobrin Draganov Breakdown of academic impact, for papers by Cornell Allen Breakdown of academic impact, for papers by Xiang Ao Breakdown of academic impact, for papers by Catalina Martínez Breakdown of academic impact, for papers by Estela Noguera-Ortega Breakdown of academic impact, for papers by Jaina M. Patel Breakdown of academic impact, for papers by Judit Fazekas Breakdown of academic impact, for papers by Chris Twitty Breakdown of academic impact, for papers by Robert Weth
Rankless by CCL
2026